Circadian Health, the first and only virtual-first provider specializing in cardiometabolic care across all 50 states, announced a strategic partnership with Tenovi, a leading provider of over 40 next-generation cellular-connected remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) devices. As Circadian continues to rapidly scale its virtual-first specialty care model, the addition of Tenovi’s advanced RPM solutions will further support the growing demand for seamless, real-time remote patient care. This collaboration enhances Circadian’s hospital-at-home model, empowering payers and employers to expand chronic disease management, drive earlier interventions, and improve patient outcomes.

Health Technology Insights: Archerfish Precision Diagnostics Launches, Advancing Diagnostic Innovation

Tenovi’s healthcare IoT platform and Cellular Gateway facilitate seamless connectivity for a wide range of cellular and Bluetooth-enabled RPM and RTM devices. These devices automatically transmit real-time patient data to the Tenovi Cloud, eliminating the need for syncing or apps. This cellular-based connectivity ensures that even patients facing housing instability can engage in remote monitoring programs, breaking down barriers to care. Circadian will roll out its RPM program with devices such as blood pressure monitors, blood glucose meters, weight scales, and pulse oximeters. The data collected is then integrated into Circadian’s virtual specialty care platform, providing specialists with real-time, actionable insights to enhance patient care and reduce costly hospital admissions.

“Circadian is committed to revolutionizing chronic care by integrating cutting-edge remote monitoring technology into our virtual-first specialty care model. Our partnership with Tenovi ensures that patients receive real-time, data-driven care, reducing emergency visits and improving long-term outcomes,” said Chuck Hector, Co-Founder and President of Circadian Health. “With seamless data transmission and AI-driven risk stratification, we are taking a proactive approach to cardiometabolic care, making high-quality specialty care more accessible, efficient, and impactful.”

Tenovi’s remote monitoring solutions make preventive care accessible to every patient population by enabling seamless, reliable monitoring. The Cellular Gateway supports a range of devices and reinforces adherence with visual reminders. Each morning, the Tenovi Gateway turns red to remind patients to take a reading and green once the measurement is transmitted—keeping them engaged and connected to their healthcare team in seconds.

Health Technology Insights: Linus Health Earns Major Recognition in Medical and Scientific Journals

“Through our partnership with Circadian, we help patients with chronic conditions like diabetes, heart failure, and COPD access timely specialty care, avoiding the long wait times that are a major contributor to costly hospital admissions,” said Iftah Mashav, Chief Growth Officer at Tenovi. “By integrating Circadian’s virtual care network with our cellular-connected devices and IoT Healthcare platform, we are empowering patients, health plans, and employers to reduce overall healthcare costs while enhancing health outcomes.”

With next-generation remote monitoring technology, Circadian and Tenovi are transforming specialty care by enabling seamless, real-time data transmission—helping payers and employers scale remote monitoring, drive earlier interventions, and improve patient outcomes.

  • 40+ devices enable payers and employers to scale remote monitoring programs.
  • No syncing. No apps—real-time data transmission via Tenovi’s Cellular Gateway.
  • Single API integration streamlines data collection and enhances care coordination.
  • FDA-cleared, cellular-enabled RPM & RTM devices provide real-time patient vitals.
  • Circadian’s AI-driven platform delivers actionable insights for proactive disease management.
  • Improved patient outcomes through early intervention and personalized treatment.

Health Technology Insights: Laminar Pharma Shares First PFS Data for LAM561 in Glioblastoma Treatment

To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com

Source – prnewswire